08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche will acquire Annapurna, gaining four preclinical adeno-associated virus (AAV) gene therapy programs. The programs include ANN-001, an AAV vector delivering alpha-1 antitrypsin ( AAT; A1AT; SERPINA1) to treat AAT deficiency; ...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Weill Cornell Medical College, Annapurna Therapeutics deal

Weill granted Annapurna an exclusive license to three preclinical gene therapy programs for alpha-1 antitrypsin deficiency (AATD), hereditary angioedema (HAE) and severe allergies. Annapurna expects to start clinical testing of the programs in 18-24 months....
07:00 , Aug 11, 2014 |  BioCentury  |  Emerging Company Profile

AAVLife: Fixing Friedreich's heart

AAVLife S.A.S. is developing an adeno-associated viral vector-based gene therapy that could become the first disease-modifying treatment for Friedreich's ataxia-associated cardiomyopathy. The therapy has the potential to decrease the risk of cardiac events and improve...
07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Frataxin (FXN; FRDA) Mouse studies suggest FXN gene therapy could help prevent or treat heart failure...